Two cases show COVID virus mutating around standard treatment remdesivir
Patients with weakened immune systems could be inadvertently helping COVID-19 develop resistance to the antiviral drug remdesivir, a new study reports.
Jan 23, 2024
0
1
Patients with weakened immune systems could be inadvertently helping COVID-19 develop resistance to the antiviral drug remdesivir, a new study reports.
Jan 23, 2024
0
1
Almost 30% of the patients in a pilot program for those with psoriasis that was devised by researchers from the Perelman School of Medicine at the University of Pennsylvania were identified as having undiagnosed, elevated ...
Jan 8, 2024
0
0
Danny Blom researched advanced models and their impact on the practice of kidney exchange.
Dec 21, 2023
0
0
Transplant recipients, especially those receiving hematopoietic stem cell transplant (HSCT), have an increased risk for vitiligo, according to a brief report published online Dec. 13 in JAMA Dermatology.
Dec 21, 2023
0
0
For patients with kidney failure, there appears to be no substantial improvement over time in the observed or adjusted Black-white mean living donor kidney transplant (LDKT) rate ratios (RRs), according to a study published ...
Dec 21, 2023
0
0
Renal dysfunction, especially chronic kidney disease, is the biggest risk factor of mortality among thrombolysed stroke patients, according to a retrospective cohort observational study published in Medicine.
Dec 13, 2023
0
0
A common diabetes medication may help some patients with treatment-resistant hypertension slightly lower their high blood pressure and lessen their risk of heart failure events such as stroke, according to an analysis of ...
Dec 5, 2023
0
1
For patients with chronic kidney disease (CKD) and type 2 diabetes, early albuminuria reduction accounts for a large proportion of the treatment effect of finerenone against CKD progression, according to a study published ...
Dec 5, 2023
0
2
From 2014 to 2021, uptake of disease-modifying treatments (DMTs) for sickle cell disease (SCD) remained low, according to a study published in the journal JAMA Network Open.
Nov 27, 2023
0
0
In a post hoc analysis of the Phase II NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney ...
Nov 10, 2023
0
1